Veenstra Timothy D
Maranatha Baptist University, Watertown, WI, USA.
Proteomics. 2016 Nov;16(22):2847-2853. doi: 10.1002/pmic.201600211. Epub 2016 Oct 14.
With the life expectancy of individuals in the developed nations reaching historic highs, the incidence of dementia within the aging population is also increasing. Of the known causes of dementia, the major culprit is Alzheimer's disease (AD). The numbers of individuals suffering from AD is expected to nearly triple over the next 35 years unless medical science can identify better methods for diagnosing and treating AD. Fortunately, proteomics technologies have not only rapidly matured in the past few decades but also have been effectively applied so that the biomarkers of AD can be more effectively vetted and analyzed. The effectiveness of the technologies described in this paper enable the efficacy of drugs aimed at treating AD to be tested much faster than the previously possible and enable the more accurate selection of patients that are suitable for clinical trials.
随着发达国家个人预期寿命达到历史新高，老年人口中痴呆症的发病率也在上升。在已知的痴呆症病因中，主要元凶是阿尔茨海默病（AD）。除非医学能够找到更好的AD诊断和治疗方法，否则预计在未来35年内，AD患者数量将几乎增加两倍。幸运的是，蛋白质组学技术在过去几十年中不仅迅速成熟，而且得到了有效应用，从而能够更有效地审查和分析AD的生物标志物。本文所述技术的有效性使得针对AD治疗的药物疗效测试比以前更快，并且能够更准确地选择适合临床试验的患者。
